Describing Real-World Rimegepant Utilization Patterns and Understanding Perceptions of Migraine Treatment Optimization from the Perspectives of Patients

Study type

• Study topic:
  Disease /health condition

  Human medicinal product
• Study type:
  Non-interventional study
• Scope of the study:
  Disease epidemiology

  Drug utilisation

  Evaluation of patient-reported outcomes
• Data collection methods:
  Primary data collection

Non-interventional study

• Non-interventional study design:
  Cross-sectional

Study drug and medical condition

• Name of medicine, other:
  Rimegepant (Nurtec 75mg ODT)
• Study drug International non-proprietary name (INN) or common name:
  RIMEGEPANT

  RIMEGEPANT SULFATE
• Anatomical Therapeutic Chemical (ATC) code:
  (N02CD06) rimegepant

  rimegepant
• Medical condition to be studied:
  Migraine

Population studied

• Short description of the study population:
  US adult participants with migraine diagnosis currently taking rimegepant. Participants must start taken rimegepant at least 3 months prior to the administering of the survey, and must have taken rimegepant within the past 30 days prior to the administering of the survey. Participants will be enrolled after providing their consent to participate in the study. ;
• Age groups:
  Adult and elderly population (≥18 years)
• Estimated number of subjects:
  500

Study design details

• Study design:
  This is a cross-sectional, observational study that will collect real-world data from a survey completed by United States participants with a migraine diagnosis currently being treated with rimegepant.
• Main study objective:
  The purpose of this research is to obtain real-world evidence (RWE) on key outcomes associated with the use of rimegepant among patients with migraine in the US population.
• Setting:
  Cognitive pre-test interviews will be conducted with migraine patients via telephone. An individual trained in cognitive interviewing will lead participants through draft survey questions, with predefined probes to understand relevance of the survey questions and patient comprehension. Prior to participating, all respondents will give their informed consent to proceed with the interview and to have their interview recorded for analysis purposes only. Participants will need to be in front of a computer to enable viewing of the moderator’s secure desktop sharing application. ; Participants for the quantitative survey will be invited by a recruiter agency who will use a multisource recruitment approach, meaning that patients will be recruited through several sources. These sources include patient panels, patient databases, social media, patient associations, and physician referrals. Recruiter patient panels include individuals who would qualify for research studies of diverse topics, and the panel participants are tagged with various demographic and disease-specific categories which will allow for targeted recruitment of patients for this study. The cross-sectional quantitative survey will be conducted online, and participants will complete a self-administered electronic screener to determine eligibility. Prior to participating, all participants will give their informed consent to proceed with the study.;